文章基本信息

标题：Selective NaV1.1 activation rescues Dravet syndrome mice from seizures and premature death
本地全文：下载
作者：Kay L. Richards ; Carol J. Milligan ; Robert J. Richardson 等
期刊名称：Proceedings of the National Academy of Sciences
印刷版ISSN：0027-8424
电子版ISSN：1091-6490
出版年度：2018
卷号：115
期号：34
页码：E8077-E8085
DOI：10.1073/pnas.1804764115
语种：English
出版社：The National Academy of Sciences of the United States of America
摘要：Dravet syndrome is a catastrophic, pharmacoresistant epileptic encephalopathy. Disease onset occurs in the first year of life, followed by developmental delay with cognitive and behavioral dysfunction and substantially elevated risk of premature death. The majority of affected individuals harbor a loss-of-function mutation in one allele of SCN1A , which encodes the voltage-gated sodium channel Na_V1.1. Brain Na_V1.1 is primarily localized to fast-spiking inhibitory interneurons; thus the mechanism of epileptogenesis in Dravet syndrome is hypothesized to be reduced inhibitory neurotransmission leading to brain hyperexcitability. We show that selective activation of Na_V1.1 by venom peptide Hm1a restores the function of inhibitory interneurons from Dravet syndrome mice without affecting the firing of excitatory neurons. Intracerebroventricular infusion of Hm1a rescues Dravet syndrome mice from seizures and premature death. This precision medicine approach, which specifically targets the molecular deficit in Dravet syndrome, presents an opportunity for treatment of this intractable epilepsy.
关键词：genetic epilepsy ; targeted drug therapy ; seizures ; Dravet syndrome ; spider venom